Revenue: As of FY2025 Q2, the actual value is USD 1.242 M.EPS: As of FY2025 Q2, the actual value is USD -2.25.EBIT: As of FY2025 Q2, the actual value is USD -2.622 M.<h3>Segment Revenue</h3><ul><li>Total Revenue: $1.2 million for the three months ended June 30, 2025, a decrease of 36.8% from $1.965 million in the same period in 2024. Revenue for the six months ended June 30, 2025, was $2.355 million, down 39.8% from $3.909 million in 2024.</li></ul><h3>Operational Metrics</h3><ul><li>Gross Profit: $0.6 million for the three months ended June 30, 2025, compared to $1.1 million in 2024, with a gross margin of 48.2% versus 57.7% in 2024. For the six months ended June 30, 2025, gross profit was $1.3 million, down from $2.3 million in 2024, with a gross margin of 54.4% compared to 58.8% in 2024.</li><li>Operating Loss: $2.762 million for the three months ended June 30, 2025, compared to $2.054 million in 2024. For the six months ended June 30, 2025, operating loss was $4.971 million, compared to $4.264 million in 2024.</li><li>Net Loss: $2.630 million for the three months ended June 30, 2025, compared to $1.595 million in 2024. For the six months ended June 30, 2025, net loss was $1.156 million, compared to $3.788 million in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: $6.613 million for the six months ended June 30, 2025, compared to $3.429 million in 2024.</li><li>Net Cash Provided by Financing Activities: $10.048 million for the six months ended June 30, 2025, compared to $24 thousand in 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company plans to merge with Vyome and sell certain assets to Biorad, continue the development of the Diabetes Bloc-Stim Neuromodulation device, and expand the Lap-Band product line both domestically and internationally. The company also aims to introduce the Lap-Band 2.0 FLEX to the market.</li><li>Non-Core Business: The company is involved in a pending merger and asset sale, which includes selling substantially all of its assets to Ninjour Health International Limited and focusing on Vyome’s business post-merger.</li></ul>

ReShape Lifesciences | 10-Q: FY2025 Q2 Revenue: USD 1.242 M